SecSonar.com

Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Halozyme Therapeutics, Inc. (HALO) is a Biotechnology company based in US with a market capitalization of $8B. Revenue grew 37.5% year-over-year and the company generated $644.6M in free cash flow. This page tracks HALO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 350 employees · IPO Mar 16, 2004

Valuation

Valuation & price

$67.12 · as of May 17, 2026 · -17.4% vs 52w high

26.2

P/E ratio

Latest-FY diluted EPS

162.96

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$80.48$67.35$54.22Jul 25Dec 25Jul 26Jul 7, 25$54.22Jul 9, 25$56.58Jul 11, 25$57.15Jul 15, 25$56.60Jul 17, 25$57.81Jul 21, 25$55.92Jul 23, 25$58.56Jul 25, 25$58.24Jul 29, 25$59.05Jul 31, 25$59.97Aug 4, 25$59.99Aug 6, 25$62.32Aug 11, 25$62.89Aug 13, 25$65.13Aug 15, 25$67.27Aug 19, 25$69.98Aug 21, 25$71.61Aug 25, 25$72.21Aug 27, 25$73.18Aug 29, 25$73.15Sep 3, 25$74.82Sep 5, 25$74.93Sep 9, 25$76.07Sep 11, 25$77.53Sep 16, 25$75.85Sep 18, 25$76.68Sep 22, 25$78.28Sep 24, 25$75.64Sep 26, 25$73.75Sep 30, 25$73.34Oct 2, 25$71.69Oct 6, 25$66.97Oct 8, 25$65.20Oct 10, 25$64.10Oct 14, 25$66.65Oct 16, 25$66.88Oct 21, 25$66.88Oct 23, 25$66.89Oct 27, 25$65.85Oct 29, 25$65.26Oct 31, 25$65.19Nov 4, 25$68.05Nov 6, 25$68.39Nov 10, 25$68.01Nov 12, 25$70.63Nov 14, 25$70.03Nov 18, 25$70.10Nov 20, 25$68.97Nov 25, 25$72.82Nov 28, 25$71.40Dec 2, 25$66.54Dec 4, 25$62.95Dec 8, 25$62.88Dec 10, 25$62.65Dec 12, 25$62.21Dec 16, 25$64.47Dec 18, 25$65.11Dec 22, 25$68.16Dec 24, 25$68.41Dec 29, 25$68.95Jan 2, 26$70.31Jan 6, 26$73.13Jan 8, 26$72.13Jan 12, 26$72.42Jan 14, 26$72.96Jan 16, 26$71.21Jan 21, 26$71.71Jan 23, 26$69.22Jan 27, 26$70.22Jan 29, 26$73.34Feb 2, 26$74.45Feb 4, 26$77.93Feb 9, 26$80.48Feb 11, 26$79.51Feb 13, 26$79.44Feb 18, 26$73.23Feb 20, 26$70.98Feb 24, 26$70.36Feb 26, 26$69.22Mar 2, 26$69.85Mar 4, 26$70.02Mar 6, 26$67.37Mar 10, 26$67.81Mar 12, 26$63.56Mar 17, 26$65.13Mar 19, 26$63.27Mar 23, 26$62.86Mar 25, 26$63.24Mar 27, 26$61.63Mar 31, 26$64.63Apr 2, 26$64.49Apr 7, 26$63.60Apr 9, 26$67.08Apr 13, 26$66.98Apr 15, 26$68.05Apr 17, 26$69.29Apr 22, 26$68.40Apr 24, 26$65.36Apr 28, 26$63.86Apr 30, 26$63.66May 4, 26$64.57May 6, 26$66.35May 8, 26$64.12May 12, 26$70.93May 14, 26$69.21May 18, 26$67.44May 20, 26$68.98May 22, 26$68.32May 28, 26$68.18Jun 1, 26$68.14Jun 3, 26$69.82Jun 5, 26$71.53Jun 9, 26$71.48Jun 11, 26$70.73Jun 15, 26$71.28Jun 17, 26$68.57Jun 22, 26$68.99Jun 24, 26$71.15Jun 26, 26$74.96Jul 2, 26$79.45
$54.2252-week range$81.23
Loading valuation history…

Fundamentals

Key fundamentals

$8B

Market cap

37.5%

Revenue growth (YoY)

78.1%

Gross margin

$644.6M

Free cash flow (USD)

$2B

Net debt

-5.5%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$146.7MFY 2017$316.6MFY 2018$151.9MFY 2019$196.0MFY 2020$267.6MFY 2021$443.3MFY 2022$660.1MFY 2023$829.3MFY 2024$1.0BFY 2025$1.4B
$146.7M$1.4B

Free cash flow by year

2016 → 2025

FY 2016$-53.5MFY 2017$132.7MFY 2018$-54.2MFY 2019$-89.5MFY 2020$53.0MFY 2021$298.0MFY 2022$235.3MFY 2023$373.3MFY 2024$468.4MFY 2025$644.6M
-$53.5M$644.6M

Gross margin by year

2021 → 2025

FY 202181.6%FY 202278.9%FY 202376.8%FY 202484.3%FY 202578.1%
81.6%78.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

6

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventExecutive DepartureJul 2, 2026Filing
  • Insider sellInsider Sell $548K · 10b5-1 PlanKrishnan Mahesh · Director · $547.8KJun 30, 2026Filing
  • Insider sellInsider Sell $3.4M · 10b5-1 PlanTorley Helen · Director, PRESIDENT AND CEO · $3.4MJun 3, 2026Filing
  • Insider sellInsider Sell $108K · 10b5-1 PlanConnaughton Bernadette · Director · $107.6KJun 2, 2026Filing
  • Insider sellInsider Sell $3.4M · 10b5-1 PlanTorley Helen · Director, PRESIDENT AND CEO · $3.4MMay 13, 2026Filing
  • 8-K eventEarnings ReleaseMay 11, 2026Filing
  • Quarterly report10-Q FiledMay 11, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 7, 2026Filing
  • Insider sellInsider Sell $103K · 10b5-1 PlanConnaughton Bernadette · Director · $103.2KMay 5, 2026Filing
  • 8-K eventCFO AppointmentApr 30, 2026Filing

Questions

Frequently asked questions

What is Halozyme Therapeutics, Inc.'s market cap?

Halozyme Therapeutics, Inc. (HALO) has a market capitalization of $8B.

What is HALO's P/E ratio?

HALO trades at a price-to-earnings ratio of 26.2, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is HALO's price-to-book (P/B) ratio?

HALO trades at 162.96 times book value per share.

Are insiders buying HALO stock?

SEC Form 4 filings show no open-market insider buys at Halozyme Therapeutics, Inc. in the last 90 days (6 sells).

Same arena

Related companies in Biotechnology

IBRX

ImmunityBio, Inc.

$7.9B

TECH

Bio-Techne Corporation

$8.1B

CORT

Corcept Therapeutics Incorporated

$7.5B

PRAX

Praxis Precision Medicines, Inc.

$7.2B

ALKS

Alkermes plc

$7.1B

KRYS

Krystal Biotech, Inc.

$9.1B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.